Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug672 | C-reactive protein Wiki | 1.00 |
| drug2725 | Oral supplement enriched in antioxidants Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 pandemic threatens patients, societies and healthcare systems around the world. The host immunity determines the progress of the disease and its lethality. The associated cytokine storm mainly affects the lungs; leading to acute lung injury with variable degrees. Modulation of cytokine production using Immunonutrition is a novel concept that has been applied to other diseases. Using specific nutrients such as n3- fatty acids and antioxidant vitamins in extraordinary doses modulate the host immune response and ameliorate the cytokine storm associated with viral diseases such as COVID-19. In this proposal, we will conduct a prospective double-blinded controlled trial for 14 days on 30 SARS-CoV-2 positive cases. The participant will be randomly assigned to two groups (n=20/each); intervention (IG) and placebo (PG) groups. The IG group will be provided with an anti-inflammatory and antioxidant oral supplement (OS) on a daily basis, while the PG will be given an isocaloric placebo. Basal and weekly nutritional screening, as well as recording of anthropometric, clinical and biochemical parameters, will be done. The main biochemical parameters include serum ferritin level, cytokine storm parameters (interleukin-6, Tumor necrosis factor-α, and monocyte chemoattractant protein 1), C-reactive protein, total leukocyte count, differential lymphocytic count and neutrophil to lymphocyte ratio. It is expected that the anti-inflammatory-antioxidant OS might help in the reduction of the COVID-19 severity with more preservation of the nutritional status of infected cases.
Description: Changes in scores of the NRS-2002 for patients with COVID-19 at the end of the study, from 0 to 7 scores, with those scores < 3 means no risk of malnutrition and >= 3 means malnutrition.
Measure: Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial Time: up to 3 monthsDescription: Change in serum ferritin at the end of the trial as ferritin is considered as a COVID-19 fatality predictor.
Measure: Change from baseline Serum ferritin level at end of the trial Time: up to 3 monthsDescription: Change in IL-6 at the end of the trial as it represent the cytokine storm and it is considered as a COVID-19 fatality predictor
Measure: Change from baseline serum Interleukin-6 concentration at end of the trial Time: up to 3 monthsDescription: Change in C-reactive protein in the serum at the end of the trial which reflect the acute phase
Measure: Change from baseline serum C-reactive protein concentration at end of the trial Time: up to 3 monthsDescription: Change in the TNF a in the serum at the end of study as it represent severity of the cytokine storm
Measure: Change from baseline serum Tumor necrosis factor-α concentration at end of the trial Time: up to 3 monthsDescription: plasma MCP-1 represent severity of the cytokine storm
Measure: Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial Time: up to 3 monthsDescription: Body weight in Kg
Measure: Change from baseline Weight at end of the trial Time: up to 3 monthsDescription: stature in cm
Measure: Height Time: up to 1 monthDescription: Claculation of BMI according to weight / square Height
Measure: Change from baseline BMI at end of the trial Time: up to 3 monthsDescription: changes of MAC in cm
Measure: Change from baseline mid arm circumference at end of the trial Time: up to 3 monthsDescription: changes of TSF in mm
Measure: Change from baseline triceps skin-fold thickness at end of the trial Time: up to 3 monthsDescription: ). The mid-arm muscle area (MAMA) will be calculated according to the following equation: {MAMA= (MAC - π x TSF)2 / 4π}.
Measure: Change from baseline MAMA at end of the trial Time: Up to 3 monthsDescription: changes in the percentage of peripheral O2 saturation by an oximeter
Measure: Change from baseline percentage of peripheral O2 saturation at end of the trial Time: up to 3 monthsDescription: changes in the degree of body temperature by infrared thermometer
Measure: Change from baseline degree of body temperature at end of the trial Time: up to 3 monthsDescription: change in the count from complete blood counts
Measure: Change from baseline count the total leukocyte at end of the trial Time: up to 3 monthsDescription: change in the count from complete blood counts
Measure: Change from baseline differential lymphocytic count at end of the trial Time: up to 3 monthsDescription: change in the count from complete blood counts
Measure: Change from baseline Neutrophil count at end of the trial Time: up to 3 monthsDescription: change in the rations calculated by division of the neutrophil count by the lymphocyte count
Measure: Change from baseline neutrophil to lymphocyte ratio at end of the trial Time: up to 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports